이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

The Impact of Left Stellate Ganglion Block on Systemic Inflammation and Neuromodulation in CABG Surgery.

2026년 8월 17일 업데이트: OMAR ABDELAZIZ ABOELFADL

The Impact of Left Stellate Ganglion Block on Systemic Inflammation and Neuromodulation in CABG Surgery

((82)) patients scheduled to undergo elective CABG by the same surgical team will be allocated randomly by computer-generated random numbers into two equal groups (n= 41).

Study groups:

Group S (Stellate Ganglion Block Group):

Patients will receive an ultrasound-guided Left stellate ganglion block prior to induction of general anesthesia. The block will be performed at the C6 level under strict aseptic precautions using 5 mL of 0.25% bupivacaine. Successful blockade will be confirmed by the appearance of ipsilateral Horner's syndrome.

Group C (Control Group):

Patients will receive standard perioperative care without stellate ganglion block and will undergo the same anesthetic and surgical management protocol as Group S.

연구 개요

상태

아직 모집하지 않음

정황

개입 / 치료

상세 설명

((82)) patients scheduled to undergo elective CABG by the same surgical team will be allocated randomly by computer-generated random numbers into two equal groups (n= 41).

Study groups:

Group S (Stellate Ganglion Block Group):

Patients will receive an ultrasound-guided Left stellate ganglion block prior to induction of general anesthesia. The block will be performed at the C6 level under strict aseptic precautions using 5 mL of 0.25% bupivacaine. Successful blockade will be confirmed by the appearance of ipsilateral Horner's syndrome.

Group C (Control Group):

Patients will receive standard perioperative care without stellate ganglion block and will undergo the same anesthetic and surgical management protocol as Group S.

Ultrasound guided left stellate ganglion block technique. Sedative dose of IV midazolam (1-2 mg) will be given to the patient in the preanesthetic room under supplemental oxygen nasal cannula 2-4L and electrocardiography (ECG) and pulse oximetry monitoring. Then, under local anesthesia 1% Lidocaine and complete aseptic conditions, arterial line will be inserted after ALLEN test for blood flow into the radial artery of either side for invasive blood pressure (IBP) monitoring and arterial blood gases (ABG) analysis. After that, the patient will be shifted to the operating room (OR) and Pulse oximetry, non-invasive blood pressure (NIBP), invasive blood pressure (IBP) and 5 lead electrocardiography (ECG) will be attached.

The patient will be positioned supine with the head tilted to the right and a thin cushion placed under the lt shoulder to better expose the neck. The skin will be disinfected, and patients will be instructed to avoid speaking, swallowing or making other movements during the procedure, raising their hands if they experience discomfort.

A trained anesthesiologist will use the SonoSite S series ultrasound machine (FUJIFILM SonoSite, Bothell, Washington, USA) to position the HFL38x/13-6 MHz high-frequency linear array probe horizontally at the C6 level. The internal jugular vein, common carotid artery and long neck muscle will be identified through transverse scanning. For patients in the SGB group, a 25-gauge needle will be inserted laterally at the level at C6, with the needle tip reaching the fascia plane of the sympathetic nerve chain, deep to the posterior fascia layer of the carotid sheath and superficial to the fascia covering the long neck muscle. After confirming negative pressure aspiration with no blood return, 5 mL of 0.25% bupivacaine will be injected into the SG. The anesthesiologist will assess the success of the SGB based on the presence of Horner's syndrome, characterized by miosis, ptosis, enophthalmos, nasal congestion, conjunctival congestion, facial redness, absence of sweating and a warm sensation. Control group patients will not receive any block even SHAM block.

General anesthesia technique and intraoperative management. Anesthesia will be induced with fentanyl (1-2 mcg /kg), Propofol (.5-1.5mg/kg) injected slowly and after ensuring adequate depth of anesthesia, rocuronium (0.9 mg/kg) will be given to facilitate endotracheal intubation with a cuffed appropriate size endotracheal tube and after ensuring the correct position and adequacy of ventilation are confirmed with capnography and lung auscultation, the tube is fixed, and the patient is ventilated (Datex-Ohmeda 7100 anesthesia machine) with 6 to 8 ml /kg predicted body weight using volume-controlled mode of ventilation. Respiratory rate is set initially to 12 breaths/ min and adjusted subsequently according to arterial blood gas (ABG) analysis to maintain normocarbia using. Central Venous Catheter, urinary catheter, and nasopharyngeal temperature probe will be inserted under completely aseptic technique. Anesthesia will be maintained with sevoflurane carried by oxygen/air mixture (the ratio is adjusted to maintain SpO2 between 94 % to 98 %), fentanyl (1:5 mic /kg/hr.) and rocuronium (0.3 mg/kg/h). Additional increments of fentanyl (2 mcg/kg) will be administered if mean arterial blood pressure (MAP) or heart rate (HR) rise in response to stressful surgical stimuli greater than 20% above baseline. The following parameters will be continuously monitored during the procedure: Heart rate and rhythm, O2 saturation by pulse oximetry (SpO2), end-tidal CO2, Invasive arterial blood pressure, central venous pressure using (CVP), Core body temperature using esophageal probe, urine output, and neuromuscular blockade using peripheral nerve stimulation.

Cardiopulmonary Bypass

  • Standardized CPB protocol for all patients:
  • Membrane oxygenator, arterial line filter.
  • Priming: saline 1000-1500 mL with 5000 IU heparin.
  • Anticoagulation: Heparin 300-400 IU/kg to maintain ACT >480 seconds.
  • Flow rate: 2.2-2.4 L/min/m².
  • Temperature: Moderate hypothermia (32-34°C) or normothermia (36-37°C) per surgeon preference (will be recorded and analyzed).
  • Myocardial protection: Antegrade cold blood cardioplegia or Custodial® per institutional standard.

During CPB:

  • Propofol infusion continued as needed for sedation.
  • Neuromuscular blockade maintained.

연구 유형

중재적

등록 (추정된)

81

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: omar abulfadl abulfadl, assistant lecturer
  • 전화번호: +201069909234
  • 이메일: omarabulfadl1@gmail.com

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

설명

Inclusion Criteria:

  1. All elderly (≥65 years) patients of both genders, as according to the World Health Organization, the chronologic age of 65 years was accepted by most developed countries in the world as a definition of "elderly" or older person. Patients scheduled for elective cardiac surgery under general anesthesia.14
  2. American Society of Anesthesiologists (ASA) physical status class II or III.
  3. Patients will be stratified according to their baseline surgical risk utilizing the EuroSCORE II tool >4%15.
  4. American Society of Anesthesiologists (ASA) physical status class II or III.

Exclusion Criteria:

  1. Pre-existing dementia or significant cognitive impairment.
  2. History of stroke or cerebrovascular disease.
  3. Contraindications to SGB (e.g., coagulopathy, local infection, or anatomical abnormalities).
  4. Preoperative use of antipsychotics or antidepressants.
  5. Sinus bradycardia <50bpm &complete heart block
  6. BMI>35
  7. Redo or emergency surgery.
  8. On preoperative mechanical ventilation and long sedation time.
  9. Low EF patients <35%.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 방지
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 삼루타

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: stellate ganglion block

Group S (Stellate Ganglion Block Group):

Patients will receive an ultrasound-guided Left stellate ganglion block prior to induction of general anesthesia. The block will be performed at the C6 level under strict aseptic precautions using 5 mL of 0.25% bupivacaine. Successful blockade will be confirmed by the appearance of ipsilateral Horner's syndrome.

ultrasound guided left stellate ganglion block in patients undergoing CABG surgery to compare with control group which not receive any block even SHAM block and show its effect on reducing inflammatory biomarkers especially il6 and its effect in reducing postoperative delirium
간섭 없음: control

Group C (Control Group):

Patients will receive standard perioperative care without stellate ganglion block and will undergo the same anesthetic and surgical management protocol as Group S.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
기간
Interleukin 6 (IL-6) level in pg/ml change from baseline
기간: 0 (baseline) and 6 hours after cardiopulmonary bypass
0 (baseline) and 6 hours after cardiopulmonary bypass

2차 결과 측정

결과 측정
측정값 설명
기간
1. Incidence of postoperative delirium
기간: day 0 to 3 days after successful extubation
A trained nurse will evaluate the patients two times (06:00-08:00 and 18:00-20:00). The confusion assessment method CAM-ICU. This method includes the following four evaluation indicators: (1) changes in mental state or fluctuations in consciousness levels during acute attacks; (2) lack of concentration; (3) confused thinking and (4) changes in level of consciousness. If both features 1 and 2 are positive and at least one of the features 3 or 4 is positive, the diagnosis is delirium. Subtypes of delirium are classified according to RASS score: hyperactive type (RASS >0), hypoactive type (RASS<0), and mixed type (alternating between hypoactive and hyperactive types).
day 0 to 3 days after successful extubation
2. Delirium severity will be assessed using the Delirium Rating Scale-Revised-98.
기간: day 0 to 3 days after successful extubation
This scale features 16 items rated by clinicians and is divided into two sections: one with 13 severity items and another with three diagnostic items. Each severity item is scored from 0 to 3 points, while the diagnostic items are rated from 0 to 2 or 3 points.
day 0 to 3 days after successful extubation
3. CRP in mg/L, neutrophil to lymphocyte ratio (NLR) and Platelet to white cell ratio (PWR).
기간: day 0 (baseline) to day 3
day 0 (baseline) to day 3
4. Creatinine baseline level in mg/dl, 24 h postoperatively, 48 h postoperatively, and the urine output was recorded on the first and second postoperative days.
기간: 0 (baseline) to 48 hours postoperative
0 (baseline) to 48 hours postoperative
6. Total intraoperative opioid consumption
기간: 0 hour From induction of anesthesia to 5 hours after induction of anesthesia
0 hour From induction of anesthesia to 5 hours after induction of anesthesia
7. Postoperative opioid consumption (MME)
기간: at 2, 6, 12, 24, and 48 hours post-extubation.
at 2, 6, 12, 24, and 48 hours post-extubation.
8. ICU length of stay
기간: From icu admission to 10 days after icu admission
From icu admission to 10 days after icu admission
9. Hospital length of stay (day from surgery to hospital discharge).
기간: From hospital admission to 10 days postoperative
From hospital admission to 10 days postoperative
10. Complications during and after the operation were monitored until the patient was discharged.
기간: From 0 hour (inter-operative) to 72 hours (postoperative)
including pleural effusion, pericardial effusion, arrhythmia, organ failure, and surgical incision infections.
From 0 hour (inter-operative) to 72 hours (postoperative)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 12월 1일

기본 완료 (추정된)

2028년 3월 1일

연구 완료 (추정된)

2028년 8월 1일

연구 등록 날짜

최초 제출

2026년 7월 30일

QC 기준을 충족하는 최초 제출

2026년 8월 17일

처음 게시됨 (실제)

2026년 8월 20일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 8월 20일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 8월 17일

마지막으로 확인됨

2026년 8월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • Lt SGB in CABG

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .